hCG Priming in Women With Diminished Ovarian Reserve

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for women with a low egg reserve (diminished ovarian reserve) who are having IVF/ICSI. They get 8 weeks of low dose hCG or placebo before a second ICSI treatment.

Életkor

18 to 40 years (both included)

Nem

Women only

A betegség stádiuma

Diminished ovarian reserve. Regular menstrual cycle of 23-35 days.

Korábbi kezelés

Must be in the 1st to 5th IVF/ICSI cycle when joining.

Biomarker vagy leletérték

AMH < 6.29 pmol/L (Elecsys® AMH assay)

A részvétel fő kizáró okai

• Malformed womb, blocked fluid-filled tube (hydrosalpinx), fibroids inside the womb lining or womb polyps
• Endometriosis stage III-IV
• Planned genetic testing of embryos or sperm taken from the testicle
• Ovarian enlargement or cysts, or vaginal bleeding of unknown cause
• Known severe illness, such as diabetes, heart, lung, liver or kidney disease, HIV, Hepatitis B/C, or certain cancers

A regiszter feltételei, szó szerint

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

• 18 és 40 év között vagy?IgenNem

Mit akar kideríteni a vizsgálat

The aim of this randomized controlled trial is to further examine the possible effects of low dose human chorionic gonadotropin (hCG) priming for eight weeks in women with diminished ovarian reserve (DOR) undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). The investigators want to retest the findings of our first study in an identical paired design (NCT04643925), as an increase of 1.5 in mean number of oocytes retrieved is clinically relevant. To incorporate the strengths of a randomized controlled trial design, women will be randomized after their first ICSI treatment to receive either hCG or placebo in a double-blinded design during an eight-week priming period preceding their second ICSI treatment. The primary outcome is the number of oocytes retrieved in the second ICSI treatment.

A vizsgálat 2 csoportja

• hCG PrimingA vizsgált kezelés

  Women in the experimental group will undergo the following treatment in order: A standard IVF/ICSI cycle (ICSI I): A standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and a GnRH antagonist (Ganirelix 0.25 mg) from stimulation day 5-6 followed by blastocyst culture and a freeze-all strategy. Priming period: hCG priming 260 IU once daily for two menstrual cycles (approximately 8 weeks). A standard IVF/ICSI cycle (ICSI I): A standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and a GnRH antagonist (Ganirelix 0.25 mg) from stimulation day 5-6 followed by blastocyst culture and a single blastocyst transfer at day 5.

  Kezelés: Choriongonadotropin alfa (hCG)

• PlaceboPlacebo, összehasonlításként

  Women in the placebo group will undergo the following treatment in order: A standard IVF/ICSI cycle (ICSI I): A standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and a GnRH antagonist (Ganirelix 0.25 mg) from stimulation day 5-6 followed by blastocyst culture and a freeze-all strategy. Priming period: Placebo (isotone NaCl) injections once daily for two menstrual cycles (approximately 8 weeks). A standard IVF/ICSI cycle (ICSI I): A standard IVF/ICSI cycle in the fixed GnRH-antagonist protocol using a daily dose of 300 IU rFSH initiated from cd 2-3 and a GnRH antagonist (Ganirelix 0.25 mg) from stimulation day 5-6 followed by blastocyst culture and a single blastocyst transfer at day 5.

  Kezelés: Isotonic NaCl (Placebo)